$TLTFF – Destroying Cancer with Light, TLTFF Theralase Technologies Inc

bullquake Newsletter

$TLTFF -=”yui_3_9_1_1_1395409778117_1895″>Destroying Cancer with Light, TLTFF Theralase Technologies Inc ——————– [LINK: http://www.facebook.com/people/BullQuake-Stocks/100000308486725] [IMG: facebook] [LINK: https://twitter.com/BullQuake] [IMG: twitter] www.BullQuake.com Recent Winners:CYTR 208%, ATHX Over 55%, DRRX 15% Stocks on Watch: NAVB, CREE, ETRM, ELED, IENT, HCTI****

**

Good Evening Everyone, We wanted to bring a new company to your attention. Theralase Technologies Inc., ticker symbol TLTFF is a newly listed foreign issue with its main counter part trading on the TSX as TLT.V, a Canadian based exchange. TLTFF however can be traded on the open market in the United States under the ticker symbol TLTFF.

We did our due diligence and we feel that TLTFF is fairly undervalued at the current price per share of 0.34. We also spoke with the company who seems very eager and confident towards gaining FDA approval on several of their applications as pre-trials and trials continue to display positive results. We also anticipate that the company will soon get all of their filings together so that their newly listed U.S. counterpart TLTFF, can become fully reporting.

Just one of TLTFFs patented technologies, TLC-1000 which is a cold laser technology for non-invasive pain management currently generates ~$2 million of revenue annually through 1200 practitioners Its also interesting to note that currently over 3,000 clinical studies worldwide have proven the success of therapeutic lasers in the healing of neural muscular-skeletal conditions. Theralase has performed a blinded randomized control study on chronic knee pain proving the clinical efficacy of Theralase therapeutic laser technology and achieving FDA 510(k) approval for chronic knee pain.

*About Theralase*

Theralase Technologies Inc. designs, manufactures and markets patented, FDA approved super-pulsed laser technology used in healing injured tissue and destroying cancer. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. Theralase lasers are FDA, Health Canada and CSA/UL approved, and have international ISO 13485 certification.

Theralases strategy includes two parts: production, marketing and distribution of the Theralase super-pulsed laser for sale to health-care practitioners (focusing on the treatment of chronic pain, sports injuries and wounds); and commercialization of (i) patented cancer treatment through progressive research, clinical trials and advancement of new technology in the direct destruction of cancers and (ii) destruction of bacteria and viruses through research utilizing patented, light-sensitive Photo Dynamic Compounds *Value Driven Milestones & Upcoming Catalysts*

Q1 12 Successful preclinical studies showing complete destruction of various brain and colon cancer cell lines in-vivo and in live animal trials using Theralase PDCs Q3 12 Bladder Cancer identified as primary target for Advanced Photo Dynamic Therapy in FDA clinical trials Q3 12 Developed commercialization path for PDC technology to FDA Phase 1/2a clinical trials Q4 13 TLC-2000 Therapeutic biofeedback medical laser to be launched to healthcare practitioners Q1 14 Entering FDA phase 1 bladder cancer clinical trials Q4 15 Successfully completed 12 month follow-up of bladder cancer clinical trial.

Also anticipating the upcoming launch of TLC-2000 Biofeedback Therapeutic Laser employing a recurring revenue model. Commence TLC-3000 and PDC small animal in vivo pre-clinical trial for cancer destruction *What Makes its Interesting*

Large U.S. Market Opportunity..

More than 56 million patients suffer from acute and chronic pain, in the U.S. with the market opportunity estimated at over $100 billion annually. The publics desire for highly effective, drug-free treatments in an aging population is creating a significant opportunity for Theralase 1. Proprietary laser technology that effectively treats pain, inflammation and heals wounds without the side effects of drugs 2. Growth strategy to expand into the U.S. market, introduce a recurring revenue model.

3. R&D into combining PDCs with laser technology to destroy cancers, bacteria, and viruses.

4. Attractive ROI.

*Proven Technology*

Cold lasers are clinically proven to be the fastest and most effective method of treating pain.

Over 3,000 clinical studies worldwide support the clinical efficacy of cold lasers.

Cold lasers have no side effects, are non-invasive and provide drug-free treatment.

Theralase cold lasers have FDA, Health Canada and CE approval.

*Other Key Notes and Interests*

Proven clinical technology (TLC-1000) Commercial therapeutic laser business and brand developed over last 17 years No debt Positive cash flow / double digit growth PDC cancer destruction in animals helps pay for human trials Competitive technical advantage (Cellular pathways: iNOS, ATP, Na+ / K+) Large addressable US market ($ billions) Future technology (Patented biofeedback technology and patented PDC cancer destruction) Opportunity for growth (revenue, profit) IP protection (multiple issued patents) Experienced management team (20+ years) Clear vision and execution strategy *Key Investment Highlights*

Developing a therapeutic compound for the $3.9 billion bladder cancer market Proven ability to develop and commercialize technologies: TLC-1000 cold laser technology for non-invasive pain management currently generates ~$2 million of revenue annually through 1200 practitioners Platform technology for development of additional cancer therapeutics Favorable preclinical data (vitro and in-vitro) in bladder and breast cancer cell lines Partnership validation: Ontario Cancer Institute at Princess Margaret Hospital University Health Network Second generation (TLC-2000) launch in 2014, along with a new recurring revenue business model Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+) Proprietary technology with strong IP portfolio: patented biofeedback technology and patented PDC cancer destruction, multiple issued patents Large addressable US and World markets (several billions of dollars) Strong financials: No debt, positive cash flow / double digit growth Experienced leadership team (20+ years) *Anti-Cancer Platform Technology*

Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Through studies conducted internally and independently Theralases PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. A recent mouse model demonstrated complete destruction of subcutaneous bladder cancer tumors. The study was an important milestone signifying that the companys leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring.

*

*

*Favorable preclinical data*

Up to 100% cancer cell kill at very low concentrations (< 0.8M) More effective at killing cancer cells than already approved therapies: (668,000x ALA, 198x Photofrin) Survival of mice up to 20 months (50 human years) after a single Theralase PDT treatment *Growth Strategy*

TLC-2000 Theralase will launch the new patented biofeedback laser system in Q4 13 using a recurring revenue model and will provide upgrade incentives to existing TLC-1000 customers.

TLC-3000 Theralase will continue R&D in combining patented Photodynamic Compounds with the companys patented laser technology to enter the cancer destruction market leading to a FDA phase 1/2a clinical trial in Q1 14.

*

*

*Key Products*

TLC-1000 Laser Treatment Target Audience: Physicians, Physiotherapists, Chiropractors and Athletic Trainers Endorsed by: Professional Sports teams including the Toronto Blue Jays, Montreal Canadians, Washington Wizards and Toronto FC.

Key Benefits 1. TLC-1000 super-pulsed technology generates the highest peak power of all Class 3 cold lasers for the greatest depth of penetration.

2. Targets three cellular healing pathways; ATP for energizing cells, iNOS for elimination of inflammation and the lipid bilayer pathway for pain removal.

3. Offers more pre-programmed treatment protocols than competitive cold lasers.

4. Can be used unattended allowing practitioners to treat multiple patients simultaneously.

TLC-2000 Laser Treatment Patented 1. Theralase will commence selling its next generation therapeutic laser, the TLC-2000, in Q4 2013.

2. The patented TLC-2000 laser has the ability to more precisely treat pain and wounds by delivering exact energy doses to precise tissue locations and has a learning feature to record the most effective treatments.

3. Theralase has commissioned clinical studies by the University of Buffalo to demonstrate the efficacy of the new biofeedback technology.

4. Cumulative ROI: Year 1: 100% Year 3: 300%, Year 5: 500% TLC-3000 Laser Treatment Patented 1. Theralase is researching and developing patented photodynamic compounds (PDCs) with patented laser technology to destroy cancers, bacteria, and viruses.

2. Success in initial results using PDCs to destroy cancer cells announced Q1 12.

3. Theralase PDCs successful in destroying breast, colon, brain and bladder cancer cells.

4. Destruction of cancer tumors in a live animal model using Theralase light activated PDCs Q1 12.

5. Cumulative ROI: Year 1: 0%, Year 3: 1100%, Year 5: 1200% *Recent News and Announcements*

Feb 13, 2014 Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra Feb 12, 2014 Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market Theralase Releases Financial Results for First Quarter 2013 2013-06-03 Theralase Launches New Head Office and Therapeutic Laser Centre 2013-05-28 Theralase Advanced Cancer Therapy Research Recognized at Major International Conference 2013-05-16 Theralase Announces 2012 Year End Financials 2013-05-02 Theralases Innovative Anti-Cancer Technology Validated at Major International Conferences 2013-04-25 Theralase Applies to TSX Venture Exchange for Warrant Extension 2013-04-01 Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 2013-03-20 Renowned Oncologist Dr. Michael Jewett Joins Theralases Medical and Scientific Advisory Board 2013-02-01 Link to Article: http://www.bullquake.com/destroying-cancer-light-tltff-theralase-technologies/

Company Website: http://www.theralase.com =”yui_3_9_1_1_1392993627393_1550″> *About BullQuake.com:*

BullQuake.com is a leader in small cap investor research with over a decade of experience in managing assets, trading, research, and technical analysis.

*Follow BullQuake.com on Twitter*https://twitter.com/bullquake *Follow BullQuake.com on Facebook*https://www.facebook.com/bullquake.stocks Sign up for the free investor news and stock alerts at BullQuake.com http://www.BullQuake.com *Download one of our application:*

*The Stock Quotes & Charts App at*https://play.google.com/store/apps/detailsid=com.StockQuote#t=W251bGwsMSwxLDIxMiwiY29tLlN0b2NrUXVvdGUiXQ..

*The Stock Alerts App at*https://play.google.com/store/apps/detailsid=com.BullQuake&hl=en Disclaimer/ Disclosure: BullQuake.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BullQuake.com has not been compensated for any stocks mentioned in this newsletter for either news publication, dissemination and profile on BullQuake.com and partnering websites. BullQuake.com currently does not hold a position in any stocks mentioned in this newsletter.

——————– DISCLAIMER – This disclaimer is to be read and fully understood before using our site, services, or joining any of our network sitesFacebook, Twitter, Partnering Sites, joining our email list, or subscribing to our text message alerts. BullQuake Marketing LLC, BullQuake.com or its employees are not registered Investment Advisers. Through use of this website viewing or using you agree to hold BullQuake.com its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. BullQuake Marketing LLC is not liable for any investment decisions by its viewers and or subscribers. It is highly recommended that BullQuake.coms viewers and or subscribers speak with a financial adviser, or a broker-dealer before making any investment decisions. BullQuake.com is written and published by BullQuake Marketing LLC, its owner and employees. Readers are advised that all content and information listed on Bullquake.com or provided to you from BullQuake Marketing LLC or its employees is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation to buy or sell any securities. BullQuake.com is owned and operated by BullQuake Marketing LLC. BullQuake Marketing LLC engaged in the business of advertising and promoting companies for monetary compensation. Any compensation received by BullQuake Marketing LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BullQuake Marketing LLC has not been compensated for any stocks mentioned in this newsletter. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of said companies of which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price. BullQuake Marketing LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. BullQuake.coms sponsored advertisements do not purport to provide an analysis of any companys financial position, operations or prospects and this is not to be construed as a recommendation by BullQuake.com or an offer or solicitation to buy or sell any security. Neither the owner of BullQuake.com nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Any opinions expressed are subject to change without notice. BullQuake.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, through their website or is available from public sources and BullQuake.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. BullQuake.com does not independently investigate the information. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewers entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit www.BullQuake.com. BullQuake.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.

*BullQuake.com*

P.O. Box 795 200 S WAYNE AVE| Waynesboro, Virginia22980| USA ———————————————————————

Related posts:

1. 4 Undervalued Stocks Set to Make Major Moves on Upcoming Catalyst and a Newly Traded Investment Idea
2. News Out! Hybrid’s World Renowned Scientist Publishes Book With Leading Publisher
3. Hot_DD,_Recaps_and_Catalysts_–_ETRM,_HCTI,_NVGT,_RGDX
4. $ELED – Energie Holdings, Inc. Enters Into New Partnership With Regent
5. Portfolio Updates – CYBK, ASKH, VTUS, HCTI, NAVB, ATOS